A biopharmaceutical company headquartered in Cambridge, United Kingdom, AstraZeneca discovers, develops, manufactures, and commercializes prescription medicines across multiple therapeutic areas. Its product portfolio spans oncology, cardiovascular disease, renal and metabolic disorders, respiratory and immunology, vaccines, and rare diseases. Notable medications include Tagrisso and Iressa for lung cancer, Lynparza for ovarian cancer, Farxiga for heart failure, Brilinta for cardiovascular protection, Symbicort and Breztri for respiratory conditions, and Soliris for rare diseases. The company also markets vaccines including Beyfortus and FluMist, as well as combination therapies across multiple indications.
Revenue streams derive from sales across primary and specialty care channels distributed through local representative offices and intermediaries in the United Kingdom, United States, Europe, and Asia. The company maintains strategic collaborations with external partners, including arrangements with Tempus for oncology-focused artificial intelligence development, IonQ for quantum computing applications in drug discovery, and CSPC Pharmaceutical Group for oral candidate development in obesity and type 2 diabetes treatment.
AstraZeneca operates at scale as a major global pharmaceutical manufacturer with a market capitalization of approximately $323 billion. The company traces its origins to 1992 and adopted its current name following a 1999 merger between Astra and Zeneca.
No 10-K filings found.